Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tasnim Rahman

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I TrialAdrienne G Waks, Elia Segui, Tianyu Li, et al.
JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I TrialAdrienne G Waks, Elia Segui, Tianyu Li, et al.
JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.
Pageof 5